Business
Sareum to Present at BioTrinity 2019 in London
Sareum to Present at BioTrinity 2019 in London.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 1474X Sareum Holdings PLC 30 April 2019 \n\n(AIM: SAR) 30 April 2019\n \nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\n \nSareum to Present at BioTrinity 2019 in London\n \nSareum Holdings plc (AIM:SAR), the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, will give a company presentation at BioTrinity 2019 in London, which takes place from 30 April - 1 May. \n \nThe presentation, to be held today at 11:05am BST, will introduce Sareum and provide an overview of its lead programmes, including SRA737, a novel Chk1 inhibitor licensed to Sierra Oncology (NASDAQ: SRRA) and its two TYK2/JAK1 kinase programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers. \n \nPresentation details are as follows:\n \nDate: Tuesday 30 April 2019\nTime: 11.05am BST \nSession: BioLaunchPad Showcase Session One\n \nA copy of the presentation will be made available on the company website after the event in the News section.\n \nBioTrinity is Europe's leading Biopartnering and Investment conference, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations. \n \nFor further information, please contact: \n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220...